Centene to Pay $166 Million to Texas in Medicaid Drug Pricing Settlement
Texas is at least the 12th state to settle with St. Louis-based Centene Corp. over allegations that it overcharged Medicaid prescription drug programs.
Drug Costs
161 - 180 of 698 Results
-
-
鈥楢n Arm and a Leg鈥: The New Cap on Medicare Drug Costs
In this episode, Julie Rovner, chief Washington correspondent for KHN, guides listeners through decades of dealings between Congress and Big Pharma.
-
KHN鈥檚 鈥榃hat the Health?鈥: Wrapping Up Summer鈥檚 Health News
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
-
For Medically Vulnerable Families, Inflation鈥檚 Squeeze Is Inescapable
Inflation hasn鈥檛 hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.
-
Inflation Reduction Act Contains Important Cost-Saving Changes for Many Patients 鈥 Maybe for You聽
The legislation, which the House is expected to pass Friday, would allow the federal government, for the first time, to negotiate the price of some drugs that Medicare buys. It also would extend the enhanced subsidies for people who buy insurance on the Affordable Care Act marketplaces.
-
Big Pharma Went All In to Kill Drug Pricing Negotiations
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn鈥檛 materialized.
By Arthur Allen -
Watch: Explaining the Nitty-Gritty of Medicare Drug Price Negotiations 鈥 And Patients’ Potential Savings
KHN chief Washington correspondent Julie Rovner discusses the Senate Democrats鈥 plans to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors, and fund enhanced subsides for ACA marketplace health plans.
-
Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations
The advocacy group American Commitment said empowering Medicare to negotiate drug prices would raid it of billions of dollars. Drug pricing experts say that that鈥檚 not the case and that such policies would instead reduce costs for the Medicare program and seniors.
By Victoria Knight and Colleen DeGuzman -
KHN鈥檚 鈥榃hat the Health?鈥: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
-
Seeking to Kick-Start Biden鈥檚 Agenda, Schumer Unveils a Bill for Medicare Drug Price Negotiations
In addition to allowing federal officials to negotiate the price that Medicare pays for some drugs, the bill would cap annual out-of-pocket drug costs for Medicare beneficiaries at $2,000. But before Democrats can pass the bill under special rules that prevent Republicans from staging a filibuster, they must get approval from the Senate parliamentarian.
-
KHN鈥檚 鈥榃hat the Health?鈥: The FDA Goes After Nicotine
The FDA is using its power to regulate tobacco products 鈥 ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN鈥檚 Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
-
A Proposal to Import Drugs from Other Countries Creates an Unusual Alliance in the Senate
As a Senate committee considered legislation to reauthorize the FDA鈥檚 user fee program, Sens. Bernie Sanders and Rand Paul agreed on a proposed amendment related to importing drugs from Canada, the U.K., and other nations.
-
KHN鈥檚 鈥榃hat the Health?鈥: Taking a Shot at Gun Control
The U.S. House passed a package of bills seeking to keep some guns out of the hands of children and teenagers, but its fate in the Senate remains a big question mark. Meanwhile, the Federal Trade Commission takes on drug and hospital prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Cori Uccello of the American Academy of Actuaries about the most recent report from Medicare鈥檚 trustees board.
-
Lawmaker Takes on Insurance Companies and Gets Personal About His Health
State Sen. Scott Wiener opens up about a weeklong stint in the hospital last year and what it鈥檚 like to live with Crohn鈥檚 disease. The San Francisco Democrat is pushing a bill that would require insurance companies to cover certain medications while patients appeal denials.
-
California Wants to Slash Insulin Prices by Becoming a Drugmaker. Can It Succeed?
Gov. Gavin Newsom proposed spending $100 million to make insulin affordable to millions of people with diabetes under a new state generic drug label, CalRx. But state officials haven鈥檛 said how much the insulin will cost patients or how the state will deal with distribution and other challenges.
By Angela Hart -
KHN鈥檚 鈥榃hat the Health?鈥: Washington鈥檚 Slow Churn
Stemming gun violence is back on the legislative agenda following three mass shootings in less than a month, but it鈥檚 hard to predict success when so many previous efforts have failed. Meanwhile, lawmakers must soon decide if they will extend current premium subsidies for those buying health insurance under the Affordable Care Act, and the Biden administration acts, belatedly, on Medicare premiums. Margot Sanger-Katz of the New York Times, Sandhya Raman of CQ Roll Call, and Rachel Cohrs of Stat News join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN鈥檚 Michelle Andrews, who reported and wrote the latest KHN-NPR 鈥淏ill of the Month鈥 episode about a too-common problem: denial of no-cost preventive care for a colonoscopy under the Affordable Care Act.
-
Medicare Surprise: Drug Plan Prices Touted During Open Enrollment Can Rise Within a Month
Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications is no bargain after prices go up.
By Susan Jaffe -
Journalists Cover the Gamut, From Rising Insulin Costs to Delays in Autism Care for Children
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
US Rep. Gaetz鈥檚 Diagnosis of What鈥檚 Driving Insulin Costs Misses the Root Cause
A diabetes diagnosis is not always related to a person鈥檚 weight or overall health, especially for those with Type 1 diabetes, who are dependent on insulin treatment for life.
By Victoria Knight and Colleen DeGuzman -
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
By Arthur Allen